Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 12:01 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1705–1728 of 21,022 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Immune System Disorders Clear all

Conditions: Adult Acute Lymphoblastic Leukemia in Remission, Childhood Acute Lymphoblastic Leukemia in Remission, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia
Interventions: nonmyeloablative allogeneic hematopoietic stem cell transplantation, donor lymphocytes, cyclosporine, total-body irradiation, fludarabine phosphate, mycophenolate mofetil, laboratory biomarker analysis, peripheral blood stem cell transplantation; Procedure · Biological · Drug + 2 more
Lead sponsor: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; Other
Eligibility: Up to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2012
U.S. locations: 3
States / cities: Portland, Oregon • Seattle, Washington

Conditions: Healthy, Pulmonary Fibrosis, Rheumatoid Arthritis
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 21 Years and older
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Type 1 Diabetes Mellitus
Interventions: Dapagliflozin, Placebo matching Dapagliflozin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 12
States / cities: Chula Vista, California • San Diego, California • Torrance, California + 9 more

Conditions: ART Adherence
Interventions: TXTXT, e-Navigation, Ecological Momentary Assessment (EMA) supported e-Navigation.; Behavioral
Lead sponsor: Florida International University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Multiple Myeloma
Interventions: Daratumumab, Pomalidomide, All-trans retinoic acid, Dexamethasone; Drug
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Asthma
Interventions: PARTICS using QVAR; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 1,220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 19
States / cities: Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 14 more

Conditions: Rheumatoid Arthritis
Interventions: SAR153191 (REGN88); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 2,023 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2020
U.S. locations: 75
States / cities: Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 66 more

Conditions: Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions: Azithromycin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 850 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2000
U.S. locations: 19
States / cities: San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 11 more

Conditions: Diabetes Mellitus, Type 1
Interventions: Klue App; Other
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Allergy
Interventions: Neo-Synalar Cream, Sodium Lauryl Sulfate Aqueous Solution (0.40%), Saline; Drug · Other
Lead sponsor: Noah Rosenberg, MD; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 206 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Fairfield, New Jersey

Conditions: Transfusion Reaction, Anemia
Interventions: Standard RBCs; Biological
Lead sponsor: New York Blood Center; Other
Eligibility: 18 Years to 99 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Valhalla, New York

Conditions: Lymphoma
Interventions: Bleomycin sulfate, Stanford V regimen, Doxorubicin hydrochloride, Etoposide, Mechlorethamine hydrochloride, Prednisone, Vinblastine, Vincristine sulfate; Biological · Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1989 – 2015
U.S. locations: 1
States / cities: Stanford, California

Conditions: Multiple Myeloma
Interventions: ARM A EARLY INTERVENTION GROUP, ARM B DELAYED INTERVENTION GROUP; Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Breast Carcinoma, Cancer Survivor, Depression, Fatigue, Leukemia, Lymphoma, Malignant Bone Neoplasm, Malignant Digestive System Neoplasm, Malignant Female Reproductive System Neoplasm, Malignant Male Reproductive System Neoplasm, Pain, Sleep Disorder, Soft Tissue Sarcoma
Interventions: Management of Therapy Complications, Quality-of-Life Assessment, Questionnaire Administration, Telephone-Based Intervention; Procedure · Other · Behavioral
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years to 39 Years
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 6
States / cities: Los Angeles, California • Aurora, Colorado • Boston, Massachusetts + 3 more

Conditions: B-cell Chronic Lymphocytic Leukemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Splenic Marginal Zone Lymphoma, Waldenström Macroglobulinemia
Interventions: therapeutic autologous lymphocytes, cyclophosphamide, aldesleukin, polymerase chain reaction, gene rearrangement analysis, lymph node biopsy, genetically engineered lymphocyte therapy, bone marrow aspiration, flow cytometry, laboratory biomarker analysis, enzyme-linked immunosorbent assay; Biological · Drug · Genetic + 2 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Not listed
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Diabetes Mellitus
Interventions: CLBS03 Low Dose, CLBS03 High Dose, Placebo; Biological
Lead sponsor: Lisata Therapeutics, Inc.; Industry
Eligibility: 8 Years to 17 Years
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 15
States / cities: San Diego, California • San Francisco, California • Aurora, Colorado + 12 more

Conditions: Diffuse Large B Cell Lymphoma
Interventions: Nivolumab, IV, 240 mg; Drug
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Cancer, Cancer Metastatic, Neoplasms, Breast Cancer, Lung Cancer, Glioblastoma, Prostate Cancer, Gynecologic Cancer, Colorectal Cancer, Sarcoma, Kidney Cancer, Bladder Cancer, Lymphoma, Leukemia, Head and Neck Cancer, Pancreas Cancer, Multiple Myeloma, Anxiety, Social Isolation, Stress, Loneliness, Melanoma, Uterine Cancer
Interventions: Elly Mobile Phone Application; Behavioral
Lead sponsor: Gillian Gresham; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Rheumatoid Arthritis
Interventions: fostamatinib, placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 67
States / cities: Anniston, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 64 more

Conditions: Rheumatoid Arthritis
Interventions: tocilizumab SC, tocilizumab IV, placebo to tocilizumab SC, placebo to tocilizumab IV, Disease-modifying antirheumatic drugs (DMARDs); Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 1,262 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 54
States / cities: Huntsville, Alabama • Tuscaloosa, Alabama • Tucson, Arizona + 48 more

Conditions: Lymphoma
Interventions: Parsaclisib, Hexal, Gazyvaro; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 6
States / cities: Gilbert, Arizona • La Jolla, California • Fairway, Kansas + 3 more

Conditions: Relapsed or Refractory Multiple Myeloma
Interventions: mRNA-2808; Drug
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 10
States / cities: Birmingham, Alabama • San Francisco, California • Atlanta, Georgia + 6 more

Conditions: Multiple Myeloma
Interventions: Lenalidomide Induction, Sequential Maintenance Therapy; Drug
Lead sponsor: Cristina Gasparetto; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Multiple Myeloma
Interventions: high dose chemotherapy then autologous hematopoietic cell transplant; Procedure
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2010
U.S. locations: 1
States / cities: Stanford, California

Search by objective public record fields.

Reduced Intensity Donor Stem Cell Transplant in Treating Patients With High Risk Acute Lymphocytic Leukemia in Complete Remission

Identification of Genes Associated With Lung Disease in Patients With Rheumatoid Arthritis

BMS - Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin in Type 1 Diabetes

Efficacy of mHealth + e-Navigator Stepped Care Intervention for ART Adherence Among Latino Men With HIV

A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma

Patient Empowered Strategy to Reduce Asthma Morbidity in Highly Impacted Populations; PeRson EmPowered Asthma RElief

Long Term Evaluation of Sarilumab in Rheumatoid Arthritis Patients (SARIL-RA-EXTEND)

A Study to Evaluate the Effects of Azithromycin on MAC Disease Prevention in HIV-Positive Patients

Study to Test Efficacy of Real-time Reminders on Apple Watch To Decrease Late or Missed Meal Boluses

Neo-Synalar Modified 48 Hour Patch Test

POOLED Red Blood Cells Prepared From Pooling 5 Leukoreduced, Irradiated RBC Units

Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Lymphoma

The Myeloma Pack: A Multi-Modality Educational Intervention Strategy to Engage Patients With Multiple Myeloma

Survivorship Care in Reducing Symptoms in Young Adult Cancer Survivors

Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma

Safety and Efficacy of CLBS03 in Adolescents With Recent Onset Type 1 Diabetes (The Sanford Project T-Rex Study)

Molecular Monitoring With Circulating Tumor DNA and Nivolumab Maintenance

Evaluating the Effect of a Mobile Audio Companion (Elly) to Reduce Anxiety in Cancer Patients

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Participants With Moderate to Severe Active Rheumatoid Arthritis

Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma

Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance Therapy

High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma